GYNECURE VAGINAL OINTMENT 6.5% W/W 6.5 %
TIOCONAZOLE : 6.5 % · DIN 02095017 · PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION
Health Canada status: CANCELLED POST MARKET
What is GYNECURE VAGINAL OINTMENT 6.5% W/W?
GYNECURE VAGINAL OINTMENT 6.5% W/W 6.5 % contains TIOCONAZOLE : 6.5 %. It is listed in the Health Canada Drug Product Database under DIN 02095017, held by PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION, supplied as OINTMENT for VAGINAL administration. Health Canada currently lists it as cancelled post market, status dated 11-Nov-2002. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02095017 |
|---|---|
| Brand name | GYNECURE VAGINAL OINTMENT 6.5% W/W |
| Generic / active ingredient | TIOCONAZOLE : 6.5 % |
| Manufacturer | PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION |
| Strength | 6.5 % |
| Dosage form | OINTMENT |
| Route of administration | VAGINAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | G01AF08 TIOCONAZOLE |
| AHFS class | 84:04.08.08 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 11-Nov-2002 |
| Original market date | 1987-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code G01AF08 TIOCONAZOLE. 0 of 7 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| GYNECURE COM.PK.VAG ONT6.5%VULVAR CRM1% W/W | 1 % | CREAM ; OINTMENT | PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION | CANCELLED POST MARKET | DIN 02171902 |
| GYNECURE COM.PK.VAG OVULE300MG VULV.CRM1%W/W | 1 % | CREAM ; SUPPOSITORY | PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION | CANCELLED POST MARKET | DIN 02171910 |
| GYNECURE EXTERNAL CREAM 1% (REFILL) | 1 % | CREAM | PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION | CANCELLED PRE MARKET | DIN 02241700 |
| GYNECURE TANDEMPK.VAG ONT6.5%/VULV.CRM1%-W/W | 6.5 % | CREAM ; OINTMENT | PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION | CANCELLED POST MARKET | DIN 02218291 |
| GYNECURE TANDEMPK.VAG OV.300MG/VULV.CRM1%W/W | 300 MG | CREAM ; SUPPOSITORY | PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION | CANCELLED POST MARKET | DIN 02218283 |
| GYNECURE VAGINAL OVULE 300MG | 300 MG | SUPPOSITORY | PFIZER CANADA INC., CONSUMER HEALTHCARE DIVISION | CANCELLED POST MARKET | DIN 02095009 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.